UK government has secured a deal of early access from foreign pharmaceutical companies for 90m doses of covid-19 vaccine. 30m will come from BioNtech/Pfizer a German/US partnership and 60m from Valneva a French firm. These are in addition to the 100 million doses of the Oxford University vaccine being developed by AstraZeneca. However, using different styles of vaccine maximizes may have the potential that one of them may probably work. A vaccine may be seen as the best chance of getting people’s lives back to normal.
UK is also urging the public to sign up to take part in trials of Covid-19 vaccines, in the hope of having 500,000 people registered as willing to take part by October. However, it is still uncertain which of the experimental vaccines may work.